Register Login

Axsome Therapeutics Inc (AXSM)

(99% Neutral) Axsome Therapeutics Inc (AXSM) Announces Enrollment Update for revenues Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process

Full text
Register to leave comments
  • News bot Jan. 30, 2026, 8:18 a.m.

    📋 Axsome Therapeutics Inc (AXSM) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 07:09:28

    Event Type: Clinical Trial Update

    Event Details:

    Axsome Therapeutics Inc (AXSM) Announces Clinical Trial Update Axsome Therapeutics Inc (AXSM) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: revenues, million
    • Diseases/Conditions: AUVELITY
    • Collaboration: respectivelySUNOSI®
    • Updated Timeline: the full year 2025, the fourth quarter 2024

    🔬 Clinical Development Pipeline (Axsome Therapeutics Inc):

    Product Type Development Stage Therapeutic Area Source
    No treatment OTHER Preclinical Narcolepsy ClinicalTrials.gov
    AXS-05 DRUG Phase PHASE3 Agitation in Patients With Dementia of the Alzheimer's Type ClinicalTrials.gov
    Placebo DRUG Phase PHASE3 Migraine ClinicalTrials.gov
    AXS-07 (MoSEIC meloxicam and rizatriptan) DRUG Phase PHASE3 Migraine ClinicalTrials.gov
    Solriamfetol DRUG Phase PHASE4 Excessive Daytime Sleepiness ClinicalTrials.gov
    AXS-05 (dextromethorphan-bupropion) DRUG Phase PHASE2 Treatment Resistant Depression ClinicalTrials.gov
    Solriamfetol 300 mg DRUG Phase PHASE3 Major Depressive Disorder ClinicalTrials.gov
    AXS-07 (meloxicam-rizatriptan) DRUG Phase PHASE3 Migraine ClinicalTrials.gov
    Solriamfetol 150 mg DRUG Phase PHASE3 Excessive Sleepiness ClinicalTrials.gov
    Solriamfetol 75mg, 150 mg, or 300 mg DRUG Phase PHASE3 Binge-Eating Disorder ClinicalTrials.gov
    AXS-12 (reboxetine) DRUG Phase PHASE3 Narcolepsy ClinicalTrials.gov
    Sham OTHER Phase PHASE2 Geographic Atrophy (GA) ClinicalTrials.gov
    Avacincaptad Pegol intravitreal solution DRUG Phase PHASE2 Geographic Atrophy (GA) ClinicalTrials.gov
    ONL1204 Opthalmic solution DRUG Phase PHASE2 Geographic Atrophy (GA) ClinicalTrials.gov
    Solriamfetol Oral Tablet DRUG Phase PHASE4 Excessive Sleepiness ClinicalTrials.gov
    AXS-02 (oral zoledronate) DRUG Phase PHASE3 Complex Regional Pain Syndrome ClinicalTrials.gov
    AXS-02 DRUG Phase PHASE3 Osteoarthritis, Knee ClinicalTrials.gov
    Bupropion SR DRUG Phase PHASE2 Major Depressive Disorder ClinicalTrials.gov
    AV-001 DRUG Phase PHASE1 Covid19-associated ARDS ClinicalTrials.gov
    Bupropion DRUG Phase PHASE3 Treatment Resistant Major Depressive Disorder ClinicalTrials.gov
    AXS-05 (dextromethorphan and bupropion) oral tablets DRUG Phase PHASE3 Major Depressive Disorder ClinicalTrials.gov
    Rizatriptan DRUG Phase PHASE3 Migraine ClinicalTrials.gov
    Meloxicam DRUG Phase PHASE3 Migraine ClinicalTrials.gov
    AV-001 Placebo Injection DRUG Phase PHASE2 Acute Respiratory Distress Syndrome ClinicalTrials.gov
    AV-001 Injection DRUG Phase PHASE2 Acute Respiratory Distress Syndrome ClinicalTrials.gov
    Solriamfetol 150 mg Oral Tablet DRUG Phase PHASE1 Narcolepsy ClinicalTrials.gov
    AXS-07 DRUG Phase PHASE3 Migraine ClinicalTrials.gov
    Other prescription wake-promoting medications or stimulants DRUG Preclinical Narcolepsy ClinicalTrials.gov
    Sunosi (solriamfetol) DRUG Preclinical Narcolepsy ClinicalTrials.gov
    Monitoring OTHER Phase PHASE4 Insomnia ClinicalTrials.gov
    Cognitive Behavioral Therapy for Insomnia (CBT-I) BEHAVIORAL Phase PHASE4 Insomnia ClinicalTrials.gov
    Solriamfetol 75 MG DRUG Phase PHASE4 Insomnia ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Axsome Therapeutics Inc
    • Ticker Symbol: AXSM

Search

News categories